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OBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) as well as the
detection of anti-infliximab antibodies (ATIs) in patients with Crohn’s disease (CD).
METHOD: Forty patients with CD under treatment at a tertiary center in southeastern Brazil were evaluated.
Their use of infliximab was continuous and regular. We analyzed and compared the differences in the IFX and
ATI levels between the patients with active CD (CDA) and those with CD in remission (CDR).
RESULTS: There was no difference in the IFX level between the CDA and CDR groups (p40.05). Eighty percent of
all patients had IFX levels above the therapeutic concentration (6-10 mg/mL). Two (9%) of the 22 patients with
active disease and four (22.2%) of the 18 patients in remission had undetectable levels of IFX. Four (66.6%) of
the six patients with undetectable levels of IFX had positive ATI levels; three of these patients were in remission,
and one had active disease. In addition, the other two patients with undetectable levels of IFX presented ATI
levels close to positivity (2.7 and 2.8 AU/ml). None of the patients with therapeutic or supratherapeutic IFX levels
had positive ATI levels.
CONCLUSIONS: The undetectable levels of IFX correlated with the detection of ATIs, which was independent of
disease activity. Immunogenicity was not the main factor for the loss of response to IFX in our study, and the
majority of patients in both groups (CDA and CDR) had supratherapeutic levels of IFX.
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’ INTRODUCTION
Crohn’s disease (CD) is an inflammatory bowel disease
characterized by chronic transmural inflammation in the
intestinal tract. The aim of the current treatments for CD,
which include corticosteroid, immunosuppressant and bio-
logical agents, is not only to control disease symptoms
but above all to achieve sustained control of the intestinal
inflammation. The introduction of biological agents in CD
treatment has historically modified the natural process of
the disease by decreasing hospitalizations (1-4). Infliximab
(IFX), a monoclonal anti-TNFa chimeric antibody, was
the first biological therapy used in CD patients. IFX binds
with high affinity to soluble TNFa in the serum and to
the transmembrane form of TNFa, neutralizing its proin-
flammatory activity. In addition, IFX induces T lympho-
cyte apoptosis, epithelial barrier recovery, and the induction
of intestinal fibroblast motility, facilitating the healing of
lesions (5,6).
The duration of biological treatment is not defined at all,
and there is still no consensus on when to suspend this
treatment approach. In patients who present an incomplete
response during maintenance treatment (secondary nonre-
sponders), the dose may be adjusted or the dose range may
be reduced or even switched to another class of drug (7,8);
this approach has been performed empirically in the majority
of Brazilian hospitals. Drug monitoring could be broadly
relevant in these scenarios of nonresponse to biological
therapy as well as in reducing adverse effects if high levels of
serum IFX are detected (4,7,9).
There are few studies concerning biological drug moni-
toring in the Brazilian inflammatory bowel disease (IBD)
patient population (10). Therefore, our aim was to ana-
lyze the serum level of IFX and the detection of ATIs in
a prospective patient cohort at a southeastern Brazilian
tertiary center and to correlate these measurements with
disease activity. This approach allowed us to evaluate
the usefulness of therapeutic drug monitoring in clinical
practice.DOI: 10.6061/clinics/2019/e824
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’ METHODS
Patients and ethics statement
CD patients who were followed at the Clinical Hospital of
the University of Campinas (UNICAMP) and were in the
maintenance phase of IFX therapy were included in the
study. Of the 154 patients using IFX in the IBD outpatient
clinic at the time of the study, 40 patients between 18 and
70 years old were selected sequentially from March 2016 to
March 2017. All patients had already received induction
therapy (0, 2, 6 weeks), followed by maintenance therapy
(5 mg/kg). Disease activity was assessed by colonoscopy
(active disease defined as a CDEIS score X5 or the presence
of deep ulcers in at least one intestinal segment) or nuclear
magnetic resonance (NMR) enterography (active disease
defined as the presence of deep ulcers in at least one intesti-
nal segment). Patients were included in the study only if they
had scheduled these complementary examinations in the
period spanning from one month before to one month after the
peripheral blood sample collection. The patients were sepa-
rated into two groups: those with active disease (CDA group)
and those with disease in remission (CDR group). Calculation
of the Crohn’s disease activity index (CDAI) was performed,
and the C-reactive protein serum level was also obtained.
Table 1 shows the clinical and demographic characteristics of
the patients included in the study.
The study was conducted in accordance with the Declara-
tion of Helsinki and was approved by the Ethics Committee
of the University of Campinas (CAAE no 53097116.2.0000.
5404). Each participant read and signed a written consent
form. The laboratory analysis was carried out at the IBD
Research Laboratory of the School of Medical Sciences,
University of Campinas (UNICAMP).
Enzyme-linked immunosorbent assay (ELISA)
Peripheral blood samples were collected just before the
new maintenance infusion and centrifuged at 3,500 rpm for
15 minutes at 4oC, and the serum aliquots were snap-frozen
and stored at -20oC. The serum samples were kept at room
temperature only during the ELISA analysis. The IFX and
ATI serum levels were detected using a quantitative ELISA
from Promonitors (Progenika Biophama, S. A. Spain) accor-
ding to the manufacturer’s instructions.
The detection level of the IFX test was 0.035 to 14.4 mg/ml,
while the adopted therapeutic range was 6 to 10 mg/ml.
Concerning the test for the presence of ATIs, it was con-
sidered positive when the level detected was 45 AU/mL,
in accordance with the manufacturer’s instructions.
Statistical analysis
All results are reported as the mean ± SEM. The
Kolmogorov-Smirnov test was used to investigate whether the
data followed a normal Gaussian distribution (p40.1). The
data were analyzed using the nonparametric Mann-Whitney
Test. Binomial logistic regression analysis was performed for
correlations between the IFX/ATI levels and clinical activity.
The level of significance was set at po0.05.
’ RESULTS
CD patients with active disease and those with CD in
remission exhibited similar serum levels of infliximab
No differences in the level of IFX could be observed when
comparing the patients in the CDA and CDR groups
(p40.05). Eighty percent (80%) of all patients had IFX levels
above the therapeutic concentration (6-10 mg/mL), and of
these patients, 18 had active disease and 14 were in remission.
Two (9%) of the 22 patients with active disease and four
(22.2%) of the 18 patients in remission had undetectable levels
of IFX (Figure 1). There was no correlation between the IFX
and ATI serum levels and disease activity (Table 2).
Immunogenicity was not the main cause of the loss
of response after IFX therapy
To investigate treatment immunogenicity, we performed
an ELISA to detect anti-drug antibodies in the peripheral
blood of all patients included in the study. ATI levels 45
AU/ml were detected in only four (10%) patients; of these
Table 1 - Demographic and clinical characteristics of the patients included in the study.
CDA Group CDR Group
Number of patients 22 18
Gender (M/F) 12/10 10/8
Age (years) 35.5 [19-59] 42.5 [18-61]
Disease duration (months) 84 [8-360] 102 [2-300]
Age at diagnosis (A1/A2/A3)* 3/18/1 2/12/4
Location (L1/L2/L3/L4)* 8/12/2/0 9/9/0/0
Behavior (B1/B2/B3)* 15/5/2 15/1/2
Perianal disease (yes/no) 12/10 8/10
Immunosuppressant use (yes/no) 16/6 10/8
Duration of anti-TNFa therapy (months) 24 [2-168] 27 [2-192]
IFX interval adjustment (yes/no)N 8/14 4/14
Previous anti-TNFa therapy (yes/no) 5/17 5/13
CDAI score 210.6 [51.6-572.2] 141.5 [53.8-497.5]
CDEIS score 9.6 [4.25-22.4]# 0 [0-3]#w
Signals of inflammation in the NMR (yes/no)f 8/0 0/4
Albumin level (g/dL) 3.4 (2-4.9) 3.6 (2.3-5)
CRP level (mg/L) 11.2 (0.09-103) 3.31 (0.37-36.8)
Numerical variables are described as the median [min, max], and categorical variables are described as absolute frequencies. *Montreal Classification.
NPatients whose IFX administration interval was adjusted to 4 or 6 weeks and who remained under this drug regimen for at least 6 months before their
blood was collected. #CDEIS scores were calculated for 14 patients in each group. /Presence of ulcers and mucosal enhancement in at least one intestinal
segment. wpo0.0001 compared with the CDA group. CDA = active Crohn’s disease. CDR = Crohn’s disease in remission. M = male. F = female. TNF = tumor
necrosis factor. CDAI = Crohn’s Disease Activity Index. CDEIS = Crohn’s Disease Endoscopic Index of Severity. NMR = Nuclear Magnetic Resonance. CRP =
C-reactive protein.
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four patients, one belonged to the CDA group and three
belonged to the CDR group.
Four (66.6%) of the six patients with undetectable levels of
IFX had positive ATI levels, and three of these patients were
in remission, while one had active disease. In addition, the
two other patients with undetectable levels of IFX (one in
remission and one with disease disease) presented with ATI
levels close to the positivity threshold (2.7 and 2.8 UA/ml).
All patients with positive ATI levels underwent combined
therapy with immunosuppressants. None of the patients
with therapeutic or supratherapeutic levels of IFX had
positive ATI levels. Figure 2 illustrates these findings.
Combined therapy with immunosuppressants did
not affect the IFX levels of the patients with active
disease or those of the patients in remission
Combination therapy involving immunosuppressants was
used by 28 (70%) patients. There was no significant diffe-
rence in the IFX levels according to immunosuppressant use
(p40.05) (Figure 3).
’ DISCUSSION
Therapy with IFX is commonly used in patients with CD
to achieve a clinical response and to maintain sustained
remission. Although most of our patients had suprather-
apeutic levels of IFX, all patients with positive or close to
positive ATI levels had undetectable levels of the drug,
regardless of the endoscopic or radiological CD activity
status. There was no correlation with CD activity in our
results. However, the levels of IFX and ATIs correlated with
each other (all patients with undetectable levels of IFX
presented positive or close to positive ATI levels) and may
be relevant in patients with active disease to improve
the therapeutic management and outcomes of CD. Indeed,
a consensus has not been reached in the literature regarding
the association between the drug levels and activity of CD.
Both negative and positive associations have been found,
and these contrasting results depend on the anti-TNFa agent
evaluated (adalimumab or infliximab) (11-14). More data are
needed to explain the variation in the drug levels. In a recent
retrospective study that evaluated 76 patients with IBD (72%
with CD) who lost responsiveness to IFX, clinical improve-
ment was observed after increasing the IFX dose regardless
of the IFX serum concentration (15). Although this study
could not confirm the usefulness of drug monitoring, other
studies have revealed that this monitoring is relevant to
anticipating the sustained long-term outcome of IFX therapy
and to improving efficacy and decreasing the risk of adverse
events during the maintenance phase of treatment (16-21).
Recently, Travis et al. (22) reported that the implementation
of uniform practices to optimize IFX therapy should include
Figure 1 - Infliximab serum levels in Crohn’s disease patients with
active disease and those in remission. For CDR, n=18; for CDA,
n=22. There was no significant difference between the groups.
CDR: Group of patients with Crohn’s disease in remission; CDA:
Group of patients with active Crohn’s disease.
Table 2 - Numerical data from the logistic regression analysis
of the correlation between the IFX (infliximab) or ATI (anti-
infliximab antibody) serum levels and disease activity.
IFX level (mg/ml) ATI level (AU/ml)
p value p40.05 p40.05
Odds ratio (95% CI) 0.429 (0.04-4.578) 0.111 (0.005-2.727)
Figure 2 - Comparison between the infliximab serum levels of
Crohn’s disease patients with positive and negative levels of anti-
infliximab antibodies. For ATI+, n=4; for ATI -, n=36. The symbol
* indicates a significant difference (po0.05) between the groups,
ATI- versus ATI+. ATI: anti-infliximab antibody.
Figure 3 - Infliximab serum levels compared between Crohn’s
disease patients stratified by their concomitant immunosuppres-
sant use. For IMS+, n=28; for IMS -, n=12, *po0.05 is considered
statistically significant versus the IMS+group. IMS: immuno-
suppressant.
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a standardized drug monitoring approach with a goal of
producing IFX levels greater than 5 mg/mL. Moreover, when
the IFX concentration after week 14 and the ATI levels were
added to the clinical data, dose and/or range changes based
on actual dosing were recommended in 48/50 (96%) patients
(23). Brandse et al. (24) showed that IFX levels below 3 mg/
mL increase the risk of developing ATIs. The identification of
influential pharmacokinetic factors and ATIs improves the
prediction of IFX levels, potentially making individualized
dosing and cost reduction possible (19,25,26).
We did not find any difference in the IFX levels dependent
on immunosuppressant use (Figure 3), which agrees with the
findings of other studies in the literature, such as the study
by Oh et al. (14). The patients who received a concomitant
immunosuppressant tended to have a lower incidence of
antibody formation than those who did not receive a con-
comitant immunosuppressant, as reported by Buurman et al.
(10% vs 26%, respectively), but the difference was not
significant (27). The effect of immunosuppressants may be
more important in patients treated with episodic IFX (0% vs
60%, respectively, po0.018) than in patients receiving
scheduled maintenance treatment (13% vs 15%, respec-
tively, p=9) (27).
Regarding the ATI levels, the available data suggest that
the presence of ATIs may have a negative impact on the
clinical outcome, although this effect is not absolute (28). In a
retrospective study, the presence of ATIs reduced the
likelihood that IFX intensification would restore the clinical
effect of IFX in patients with secondary loss of response (29).
Thus far, measuring IFX levels along with ATI levels has
been suggested to be useful in patients with loss of secon-
dary response. Afif et al. (29) showed that in patients with
subtherapeutic concentrations of IFX and negative ATI levels,
IFX dose escalation was superior to switching to another
biological compound. In contrast, ATI positivity does not
affect the rate of clinical remission, endoscopic improvement
or C-reactive protein (CRP) level in CD patients under long-
term infliximab therapy (18). Although our data indicate a low
number of patients with positive ATI levels, we believe that
the interpretation of the ATI level status should be made with
caution. In fact, there is also evidence that the concentration of
ATIs may fluctuate and even drop below detectable levels
after infliximab intensification (30). Moreover, negative ATI
levels are possible in the presence of higher serum levels of
IFX. In addition, the ATI assay measures the serum levels of
free ATIs but lacks sensitivity towards IgG4 because only the
bivalent fraction is detected (31,32). However, the relevance
of these data lies in showing how the detected ATI levels
may affect clinical practice. Patients with positive ATI levels
usually have undetectable drug levels, and this clinical situ-
ation can be better classified as an immunogenic nonresponse.
The practical recommendation is that ELISA ATI levels should
be measured not in all patients but mainly in those patients
with undetectable IFX levels.
The serum concentration of IFX during scheduled main-
tenance therapy predicts the patient clinical outcome. Factors
such as the formation of antibodies, pharmacokinetics and
the albumin level may modulate serum IFX and, conse-
quently, the clinical response to the therapy (27). The impact
on the development of antibodies was minimal in our
patients receiving regularly scheduled infliximab treatment.
Therefore, decreasing the IFX dose would result in a lower
cost and optimization of the drug for the majority of our
patients, and it would be a possible strategy to employ.
The main limitation of this study was the lack of longitu-
dinal data for the measurement of the IFX and ATI levels
over time and over the course of the disease (33). However,
our cross-sectional findings were very useful for obtaining an
overview of biological therapy monitoring in our center. The
main unexpected finding was the high number of patients
with supratherapeutic levels of IFX. In our institution, the
issue as to whether it is safe to reduce the dose of the drug in
these patients, considering the risk of recurrence of the
disease, will need to be discussed. Moreover, immunogeni-
city was not the main cause of loss of response after IFX
therapy in our patients, as the minority of the CDA group
presented positive ATI levels, but a correlation with the
undetectable levels of IFX was detected. The main cause of
continued disease in our patients with adequate or supra-
therapeutic serum levels of IFX with negative ATI levels was
probably the development of other proinflammatory path-
ways that do not depend on TNF-a.
In summary, the introduction of drug monitoring for anti-
TNFa agents, including drug level and ATI detection, may
allow for more personalized therapeutic management with
better dose adjustment or even a change to another drug
with a different action mechanism. Furthermore, this may
reduce expenses associated with medication, mainly in the
patients with supratherapeutic drug levels.
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